It's widely recognized that health care is a growing expense for many Americans. However, what health care companies do with ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Houston-based Moleculin Biotech, Inc., currently trading at $0.80 and showing a market capitalization of $2.4 million, has entered into an agreement with an investor to modify certain terms of ...

Prices have been fixed for drugs and formulations meant for diabetes, hypertension, heart issues, bacterial infections, ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...